Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Datopotamab deruxtecan |
Synonyms | |
Therapy Description |
Datopotamab deruxtecan (DS-1062a) is an antibody-drug conjugate (ADC) comprising an antibody that targets TROP2 linked to the topoisomerase I inhibitor DXd, which may induce apoptosis and inhibit tumor growth (PMID: 34413126). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Datopotamab deruxtecan | Dato-DXd|DS1062a|DS 1062a|DS-1062a | TROP2 Antibody 13 | Datopotamab deruxtecan (DS-1062a) is an antibody-drug conjugate (ADC) comprising an antibody that targets TROP2 linked to the topoisomerase I inhibitor DXd, which may induce apoptosis and inhibit tumor growth (PMID: 34413126). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03401385 | Phase I | Datopotamab deruxtecan | First-in-human Study of DS-1062a for Advanced Solid Tumors | Active, not recruiting | USA | 1 |
NCT04484142 | Phase II | Datopotamab deruxtecan | Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05) | Active, not recruiting | USA | NLD | ITA | HUN | FRA | ESP | DEU | 3 |
NCT05374512 | Phase III | Eribulin Nab-paclitaxel Paclitaxel Datopotamab deruxtecan Carboplatin Capecitabine | A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy | Active, not recruiting | USA | TUR | POL | ITA | HUN | GBR | FRA | ESP | DEU | CAN | BRA | BEL | ARG | 10 |
NCT05866432 | Phase II | Datopotamab deruxtecan | Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases (TUXEDO-2) | Recruiting | AUT | 0 |
NCT06279728 | Expanded access | Datopotamab deruxtecan | Medical Access Program for Datopotamab Deruxtecan in NSCLC Patients | Available | USA | ESP | DEU | CHE | CAN | AUT | 1 |
NCT06176261 | Phase II | Datopotamab deruxtecan | DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs | Recruiting | USA | 0 |
NCT06103864 | Phase III | Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Datopotamab deruxtecan + Durvalumab Datopotamab deruxtecan Carboplatin + Gemcitabine + Pembrolizumab | A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer | Recruiting | USA | TUR | POL | ITA | GBR | FRA | ESP | DEU | CAN | BRA | AUS | ARG | 11 |
NCT06417814 | Phase III | Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Datopotamab deruxtecan + Osimertinib Datopotamab deruxtecan | A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung15) | Recruiting | USA | POL | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | 10 |
NCT06508216 | Phase Ib/II | Datopotamab deruxtecan + Durvalumab Datopotamab deruxtecan | A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer (COMPASS-TNBC) | Recruiting | FRA | 0 |
NCT04656652 | Phase III | Docetaxel Datopotamab deruxtecan | Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) | Active, not recruiting | USA | ROU | POL | NLD | ITA | HUN | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUS | ARG | 9 |
NCT05629585 | Phase III | Datopotamab deruxtecan Capecitabine + Pembrolizumab Datopotamab deruxtecan + Durvalumab | A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy | Recruiting | USA | SWE | ITA | GRC | GBR | FRA | ESP | DNK | DEU | CAN | BRA | BEL | 5 |
NCT06533826 | Phase II | Trastuzumab deruxtecan Datopotamab deruxtecan | TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd (TRADE DXd) | Not yet recruiting | USA | 0 |
NCT05489211 | Phase II | Capecitabine + Datopotamab deruxtecan Datopotamab deruxtecan + Durvalumab + Saruparib Capecitabine + Datopotamab deruxtecan + Nivolumab Carboplatin + Datopotamab deruxtecan Datopotamab deruxtecan + Fluorouracil Datopotamab deruxtecan + Saruparib Datopotamab deruxtecan + Durvalumab Datopotamab deruxtecan + Fluorouracil + Nivolumab Bevacizumab + Datopotamab deruxtecan + Fluorouracil + Leucovorin Bevacizumab + Capecitabine + Datopotamab deruxtecan Datopotamab deruxtecan | Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours | Recruiting | USA | TUR | POL | ITA | GBR | FRA | ESP | DEU | CHE | CAN | 4 |
NCT05104866 | Phase III | Gemcitabine Capecitabine Datopotamab deruxtecan Vinorelbine Eribulin | A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) | Active, not recruiting | USA | POL | NLD | ITA | HUN | GBR | FRA | ESP | DEU | CAN | BRA | BEL | ARG | 7 |
NCT04940325 | Phase II | Datopotamab deruxtecan | Datopotamab (DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer (ICARUS-LUNG01) | Active, not recruiting | FRA | 0 |